The US FDA's Gastrointestinal Drugs Advisory Committee vote supporting the relaunch of the irritable bowel syndrome therapy Zelnorm (tegaserod) is a milestone event in the Gottlieb-era at the agency.
It is an almost self-conscious effort by FDA to declare the “Safety First” era that defined regulatory decisions a decade...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?